Public Citizen chief hopes to "influence" FDA

Curious about Sid Wolfe's new role as an advisory committee member at the FDA? Ed Silverman at Pharmalot interviewed the consumer activist about his hopes for influence at the agency. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.